Authors

Latest:

Dr. Li Reviews Afatinib Data From the LUX-Lung 3 Trial

Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

Ticiana A. Leal, MD

Ticiana A. Leal, MD, is an associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia; as well as medical director of the Clinical Trials Office and leader of the Lung Cancer Disease Team at the Winship Cancer Institute of Emory University

Latest:

Dr Leal on Clinical Considerations Surrounding the Diagnosis of LEMS in Patients With Lung Cancer

Ticiana Leal, MD, discusses clinical considerations surrounding the diagnosis of LEMS in patients with lung cancer.

Ticiana A. Leal, MD, University of Wisconsin School of Medicine

Ticiana Leal, MD, University of Wisconsin-Madison

Latest:

Updates in Systemic Therapy for Non-Metastatic Lung Cancer

Tiffany A. Traina, MD

Latest:

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial

Tiffany Traina, MD, FASCO, highlights results from the phase 3 TROPION-Breast02 trial showing that datopotamab deruxtecan significantly improved progression-free and overall survival versus chemotherapy in patients with previously untreated triple-negative breast cancer who were not eligible for immunotherapy.

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

Latest:

Addressing Treatment Gaps in HER2+ MBC

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Tiffany Traina, MD, Memorial Sloan Kettering Cancer Center

Latest:

Consequences of Chemotherapy-Induced Neutropenia

A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.

Tim F. Greten, MD

Latest:

Dr. Greten on the Tumor Microbiome and Antitumor Immunity in Liver Cancer